In this study, we report the improvement of the docetaxel response of prostate cancer xenografts PAC120 by combination with trastuzumab (Herceptin®, Roche, Neuilly sur Seine, France), a humanised anti-HER2 antibody, and the idea is to understand tumour biological mechanism after combination. Here, ERBB2 is linked to prostate cancer.